___________________________________________________________________________ Colorectal Cancer 259. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet . 2009;373(9666):811-820. 260. Valentini V, Beets-Tan R, Borras JM, et al. Evidence and research in rectal cancer. Radiother Oncol . 2008;87(3):449-474. 261. Abraha I, Aristei C, Palumbo I, et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev . 2018;(10):CD002102. 262. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med . 2006;355(11):1114- 1123. 263. Weiser MR, Quah HM, Shia J, et al. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg . 2009;249(2):236-242. 264. De Caluwé L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev . 2013;2:CD006041. 265. Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR. Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys . 2012;84(4):949-954. 266. Benson AB III, Venook AP, Bekaii-Saab T, et al. Colon cancer, version 3.2014. J Natl Compr Canc Netw . 2014;12(7):1028-1059. 267. National Cancer Institute. NCI Dictionary of Cancer Terms. Available at https://www.cancer.gov/publications/dictionaries/ cancer- terms. Last accessed March 7, 2022. 268. Dragovich T, Tsikitis VL. Colon Cancer Medication. Available at https://emedicine.medscape.com/article/277496-medication. Last accessed March 7, 2022. 269. Cagir B, Trostle DR. Rectal Cancer Medication. Available at https://emedicine.medscape.com/article/281237-medication. Last accessed March 7, 2022. 270. Wang JH, King TM, Chang MC, Hsu CW. Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis. World J Gastroenterol . 2012;18(38):5427-5433. 271. Saif MW, Relias V, Syrigos K, Gunturu KS. Incidence and management of ziv-aflibercept related toxicities in colorectal cancer. World J Clin Oncol . 2014;5(5):1028-1035. 272. Matin K. Colon Cancer Treatment Protocols. Available at https://emedicine.medscape.com/article/2005487-overview. Last accessed March 7, 2022. 273. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol . 2005;23(28):7125-7134. 274. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg . 2002;235(6):759-766. 275. Rodriguez-Bigas MA, Herrera L, Petrelli NJ. Surgery for recurrent rectal adenocarcinoma in the presence of hydronephrosis. Am J Surg . 1992;164(1):18-21. 276. Vermaas M, Ferenschild FT, Verhoef C, et al. Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. Eur J Surg Oncol . 2007;33(4):452-458. 277. Ogunbiyi OA, McKenna K, Birnbaum EH, Fleshman JW, Kodner IJ. Aggressive surgical management of recurrent rectal cancer—is it worthwhile? Dis Colon Rectum . 1997;40(2):150-155. 278. Weiser MR, Landmann RG, Wong WD, et al. Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum . 2005;48(6):1169-1175. 279. Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol . 2011;12(11):1032-1044. 280. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ . 1993;306(6880):752-755. 281. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol . 1995;13(6):1303-1311. 282. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first- line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet . 2000;356(9227):373-378. 283. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol . 2001;19(21):4097-4106. 284. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol . 2001;19(8):2282- 2292. 285. Díaz-Rubio E, Tabernero J, Gómez-España A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol . 2007;25(27):4224-4230.
Powered by FlippingBook